RVC invested in the development of drugs for blindness
RetroSense Terapeutics, a private American biotechnology company, develops drugs based on gene therapy and opto-genetics to restore the vision of patients suffering from pigmented rhinitis and age-related macular dystrophy. At a ceremony held on Friday, November 13, in Ann Arbor, the RetroSense Therapeutics round was recognized as the "Deal of the Year" in the Midwest of the United States. Currently, there are no registered drugs on the market for the treatment of these diseases. The basis for the development is the unique research of scientists from Wayne State University and Massachusetts General Hospital, the rights to which are owned by RetroSense. RetroSense is managed by a team of managers with experience in product and technology development from invention to completion of clinical trials. RBV Capital Venture Fund under the management of RusBio Ventures Management Company was formed at the end of 2014 by venture market professionals with successful experience of domestic and international transactions in the field of biomedicine.
The Fund became the first large independent investment partnership established in the Russian Federation. The anchor private investor of the Fund is the leading Russian private pharmaceutical company CJSC R-Pharm. For more information, please contact: